In a recent comprehensive pan-cancer study examining MDM2/X amplification across 250 studies involving 30,118 patients, it was found that amplification of MDM2/X expression predicts a poor response to immunotherapy and is associated with shorter overall survival.47 Here, MDM2 is linked to cancer.